Five Prime Therapeutics Inc (FPRX) 22.13 $FPRX
Seattle Genetics down on ASH presentations
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:37AM CST
SGEN: 32.25 (-1.49), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), BMY: 58.75 (-0.93), CELG: 114.49 (-2.25), FPRX: 22.13 (-1.12)
Five Prime Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Fri Dec 05, 1:39AM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the Oppenheimer 25 Annual Healthcare Conference on Wednesday, December 10 at 3:55 PM Eastern Time. The conference will take place at the Crowne Plaza Hotel in New York City.
FPRX: 22.13 (-1.12)
Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Trial Evaluating FPA144 in Gastric Cancer
GlobeNewswire - Thu Dec 04, 3:05PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing in its Phase 1 clinical trial of FPA144, an anti-FGF receptor 2b antibody. FPA144 is designed to inhibit tumor growth by preventing the binding of certain fibroblast growth factors to FGF receptor 2b (FGFR2b) and directly kill tumor cells in a process called antibody-dependent cell-mediated cytotoxicity (ADCC). FPA144 is being developed initially as a monotherapy for refractory gastric cancer, a significant unmet medical need that may warrant an accelerated development and registration path.
FPRX: 22.13 (-1.12)
Insider Trading Alert - DATA, LNKD And FPRX Traded By Insiders
at The Street - Wed Dec 03, 10:15AM CST
Stocks with insider trader activity include DATA, LNKD and FPRX
LNKD: 219.90 (+2.54), DATA: 80.59 (-2.63), FPRX: 22.13 (-1.12)
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 104.43 (-2.29), KBIO: 1.80 (-0.10), PFE: 30.95 (-0.70), ADMP: 5.29 (+0.40), GSK: 42.42 (-0.93), NVS: 93.52 (-0.82), FPRX: 22.13 (-1.12)
The Zacks Analyst Blog Highlights:BioMarin, Prosensa, Five Prime Therapeutics, AbbVie, Amgen, Biogen and Vertex
PR Newswire - Fri Nov 28, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the BioMarin (Nasdaq:BMRN-Free Report), Prosensa (Nasdaq:RNA-Free Report), Five Prime Therapeutics (Nasdaq:FPRX-Free Report), AbbVie (NYSE:ABBV-Free Report), Amgen (Nasdaq:AMGN-Free Report), Biogen (Nasdaq:BIIB-Free Report) and Vertex (Nasdaq:VRTX-Free Report).
AMGN: 164.53 (-1.55), FPRX: 22.13 (-1.12)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 3.89 (-0.11), BIB: 128.83 (-3.16), INCY: 74.65 (-1.27), PFE: 30.95 (-0.70), IBB: 306.10 (-3.95), DRGS: 52.31 (-1.38), BIND: 5.82 (+0.02), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), ONTY: 2.02 (+0.31), ECYT: 6.25 (-0.06), BIS: 46.11 (+0.99), CLVS: 55.15 (+0.32), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), ARIA: 6.34 (-0.13), IRY: 47.43 (-0.71), IXJ: 101.03 (-1.47), FPRX: 22.13 (-1.12)
Five Prime Therapeutics Up on Deal with Bristol-Myers - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 3:30PM CST
Five Prime Therapeutics, Inc. announced that it has entered into an agreement with Bristol-Myers Squibb Company.
ACT: 259.00 (-4.00), AMAG: 40.04 (-0.79), BMY: 58.75 (-0.93), FPRX: 22.13 (-1.12)
Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV Therapy Closer to EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 9:54AM CST
BioMarin's (BMRN) high risk - high reward decision to acquire Prosensa (RNA) was a key event in the biotech sector last week.
BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), BMRN: 91.52 (-1.38), RNA: 18.76 (-0.21), AMGN: 164.53 (-1.55), ABBV: 65.27 (-1.76), FPRX: 22.13 (-1.12)
Five Prime Therapeutics to Present at The 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 3:11PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the 26 Annual Piper Jaffray Healthcare Conference on Wednesday, December 3 at 12:30 PM Eastern Time. The conference will take place at the Palace Hotel in New York City.
FPRX: 22.13 (-1.12)
Five Prime Therapeutics, Inc. (FPRX) in Focus: Stock Soars 31.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 8:18AM CST
Five Prime Therapeutics, Inc. (FPRX) was a big mover last session, as the company saw its shares rise by over 31% on the day.
ANIP: 54.28 (+2.33), AMAG: 40.04 (-0.79), AFFX: 8.94 (-0.36), FPRX: 22.13 (-1.12)
Lions Gate and Tesla are big market movers
AP - Mon Nov 24, 3:48PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
TSLA: 207.00 (-1.88), RNA: 18.76 (-0.21), UTX: 112.15 (-1.89), LGF: 31.85 (-0.99), TSL: 8.82 (-0.30), XOM: 86.60 (-2.60), FPRX: 22.13 (-1.12), DENN: 10.35 (+0.14)
Five Prime in cancer drug deal with Bristol-Myers
AP - Mon Nov 24, 3:20PM CST
NEW YORK (AP) — Five Prime Therapeutics said Monday that it will study a cancer drug regimen that combines one of its drugs with a therapy developed by Bristol-Myers Squibb.
BMY: 58.75 (-0.93), FPRX: 22.13 (-1.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST
CIMT: 8.73 (unch), CLRB: 3.09 (+0.09), MPX: 6.48 (-0.03), FATE: 3.69 (+0.01), TTPH: 31.57 (-0.39), PHMD: 1.37 (-0.10), BIND: 5.82 (+0.02), AXPW: 1.20 (+0.02), CANF: 3.49 (+0.03), SYN: 1.47 (-0.04), RNA: 18.76 (-0.21), CLIR: 7.67 (-0.32), VSCI: 1.16 (-0.06), OCRX: 6.10 (-0.05), GALE: 1.69 (unch), REI: 8.61 (+0.06), OGEN: 0.80 (-0.08), PTP: 73.13 (-0.24), FPRX: 22.13 (-1.12)
Bristol-Myers and Five Prime team up in cancer
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 8:29AM CST
BMY: 58.75 (-0.93), FPRX: 22.13 (-1.12)
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types
GlobeNewswire - Mon Nov 24, 7:59AM CST
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb's investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime's monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R). The Phase 1a/1b study will evaluate the combination of Opdivo and FPA008 as a potential treatment option for patients with non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, pancreatic cancer, colorectal cancer and malignant glioma. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trademark for nivolumab.
BMY: 58.75 (-0.93), FPRX: 22.13 (-1.12)
Five Prime Therapeutics (FPRX) Upgraded From Sell to Hold
at The Street - Tue Nov 18, 8:19AM CST
Five Prime Therapeutics (FPRX) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
FPRX: 22.13 (-1.12)
Five Prime Therapeutics Initiates Dosing of Rheumatoid Arthritis Patients in Its Phase 1 Clinical Trial of FPA008
GlobeNewswire - Mon Nov 17, 3:50PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing of rheumatoid arthritis (RA) patients in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R). FPA008 is being developed as a potential treatment for RA and solid tumors. FPA008 has two modes of action in RA, blocking the production of multiple inflammatory cytokines and directly inhibiting the activity of osteoclasts, thus preventing bone erosion.
FPRX: 22.13 (-1.12)
Five Prime Therapeutics to Present Data From Healthy Volunteer Cohorts in Phase 1 Trial of FPA008 at the 2014 ACR/ARHP Annual Scientific Meeting
GlobeNewswire - Thu Nov 13, 3:08PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced that it will present results from the healthy volunteer cohorts in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF-1R). The results will be featured in a poster presentation titled "A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF-1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results" at the 2014 American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting. The meeting is being held November 14-19, 2014 in Boston, Massachusetts, and the poster presentation is scheduled to take place on Monday, November 17 from 9:00 am to 11:00 am, with the poster viewable from 8:30 am to 4:00 pm. (Presentation Number 1493). The abstracts are available in the online meeting supplement: http://www.acrannualmeeting.org/wp-content/up...ement2.pdf.
FPRX: 22.13 (-1.12)
Seattle Genetics down on ASH presentations
Seeking Alpha - at Seeking Alpha - Mon Dec 08, 11:37AM CST
SGEN: 32.25 (-1.49), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), BMY: 58.75 (-0.93), CELG: 114.49 (-2.25), FPRX: 22.13 (-1.12)
Five Prime Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference
GlobeNewswire - Fri Dec 05, 1:39AM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the Oppenheimer 25 Annual Healthcare Conference on Wednesday, December 10 at 3:55 PM Eastern Time. The conference will take place at the Crowne Plaza Hotel in New York City.
FPRX: 22.13 (-1.12)
Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Clinical Trial Evaluating FPA144 in Gastric Cancer
GlobeNewswire - Thu Dec 04, 3:05PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing in its Phase 1 clinical trial of FPA144, an anti-FGF receptor 2b antibody. FPA144 is designed to inhibit tumor growth by preventing the binding of certain fibroblast growth factors to FGF receptor 2b (FGFR2b) and directly kill tumor cells in a process called antibody-dependent cell-mediated cytotoxicity (ADCC). FPA144 is being developed initially as a monotherapy for refractory gastric cancer, a significant unmet medical need that may warrant an accelerated development and registration path.
FPRX: 22.13 (-1.12)
Insider Trading Alert - DATA, LNKD And FPRX Traded By Insiders
at The Street - Wed Dec 03, 10:15AM CST
Stocks with insider trader activity include DATA, LNKD and FPRX
LNKD: 219.90 (+2.54), DATA: 80.59 (-2.63), FPRX: 22.13 (-1.12)
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 104.43 (-2.29), KBIO: 1.80 (-0.10), PFE: 30.95 (-0.70), ADMP: 5.29 (+0.40), GSK: 42.42 (-0.93), NVS: 93.52 (-0.82), FPRX: 22.13 (-1.12)
The Zacks Analyst Blog Highlights:BioMarin, Prosensa, Five Prime Therapeutics, AbbVie, Amgen, Biogen and Vertex
PR Newswire - Fri Nov 28, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the BioMarin (Nasdaq:BMRN-Free Report), Prosensa (Nasdaq:RNA-Free Report), Five Prime Therapeutics (Nasdaq:FPRX-Free Report), AbbVie (NYSE:ABBV-Free Report), Amgen (Nasdaq:AMGN-Free Report), Biogen (Nasdaq:BIIB-Free Report) and Vertex (Nasdaq:VRTX-Free Report).
AMGN: 164.53 (-1.55), FPRX: 22.13 (-1.12)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 3.89 (-0.11), BIB: 128.83 (-3.16), INCY: 74.65 (-1.27), PFE: 30.95 (-0.70), IBB: 306.10 (-3.95), DRGS: 52.31 (-1.38), BIND: 5.82 (+0.02), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), ONTY: 2.02 (+0.31), ECYT: 6.25 (-0.06), BIS: 46.11 (+0.99), CLVS: 55.15 (+0.32), AZN: 71.80 (-1.80), MRK: 57.72 (-1.62), ARIA: 6.34 (-0.13), IRY: 47.43 (-0.71), IXJ: 101.03 (-1.47), FPRX: 22.13 (-1.12)
Five Prime Therapeutics Up on Deal with Bristol-Myers - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 3:30PM CST
Five Prime Therapeutics, Inc. announced that it has entered into an agreement with Bristol-Myers Squibb Company.
ACT: 259.00 (-4.00), AMAG: 40.04 (-0.79), BMY: 58.75 (-0.93), FPRX: 22.13 (-1.12)
Biotech Stock Roundup: BioMarin to Acquire Prosensa, AbbVie HCV Therapy Closer to EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 9:54AM CST
BioMarin's (BMRN) high risk - high reward decision to acquire Prosensa (RNA) was a key event in the biotech sector last week.
BIIB: 344.49 (+2.16), VRTX: 118.55 (-2.23), BMRN: 91.52 (-1.38), RNA: 18.76 (-0.21), AMGN: 164.53 (-1.55), ABBV: 65.27 (-1.76), FPRX: 22.13 (-1.12)
Five Prime Therapeutics to Present at The 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 3:11PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX) (Five Prime), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that Lewis T. "Rusty" Williams, M.D., Ph.D., President and Chief Executive Officer of Five Prime, will present at the 26 Annual Piper Jaffray Healthcare Conference on Wednesday, December 3 at 12:30 PM Eastern Time. The conference will take place at the Palace Hotel in New York City.
FPRX: 22.13 (-1.12)
Five Prime Therapeutics, Inc. (FPRX) in Focus: Stock Soars 31.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 8:18AM CST
Five Prime Therapeutics, Inc. (FPRX) was a big mover last session, as the company saw its shares rise by over 31% on the day.
ANIP: 54.28 (+2.33), AMAG: 40.04 (-0.79), AFFX: 8.94 (-0.36), FPRX: 22.13 (-1.12)
Lions Gate and Tesla are big market movers
AP - Mon Nov 24, 3:48PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
TSLA: 207.00 (-1.88), RNA: 18.76 (-0.21), UTX: 112.15 (-1.89), LGF: 31.85 (-0.99), TSL: 8.82 (-0.30), XOM: 86.60 (-2.60), FPRX: 22.13 (-1.12), DENN: 10.35 (+0.14)
Five Prime in cancer drug deal with Bristol-Myers
AP - Mon Nov 24, 3:20PM CST
NEW YORK (AP) — Five Prime Therapeutics said Monday that it will study a cancer drug regimen that combines one of its drugs with a therapy developed by Bristol-Myers Squibb.
BMY: 58.75 (-0.93), FPRX: 22.13 (-1.12)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:46AM CST
CIMT: 8.73 (unch), CLRB: 3.09 (+0.09), MPX: 6.48 (-0.03), FATE: 3.69 (+0.01), TTPH: 31.57 (-0.39), PHMD: 1.37 (-0.10), BIND: 5.82 (+0.02), AXPW: 1.20 (+0.02), CANF: 3.49 (+0.03), SYN: 1.47 (-0.04), RNA: 18.76 (-0.21), CLIR: 7.67 (-0.32), VSCI: 1.16 (-0.06), OCRX: 6.10 (-0.05), GALE: 1.69 (unch), REI: 8.61 (+0.06), OGEN: 0.80 (-0.08), PTP: 73.13 (-0.24), FPRX: 22.13 (-1.12)
Bristol-Myers and Five Prime team up in cancer
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 8:29AM CST
BMY: 58.75 (-0.93), FPRX: 22.13 (-1.12)
Bristol-Myers Squibb and Five Prime Therapeutics Announce Exclusive Clinical Collaboration to Evaluate the Combination of Investigational Immunotherapies Opdivo (nivolumab) and FPA008 in Six Tumor Types
GlobeNewswire - Mon Nov 24, 7:59AM CST
Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics, Inc. (Nasdaq:FPRX) today announced that they have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo (nivolumab), Bristol-Myers Squibb's investigational PD-1 (programmed death-1) immune checkpoint inhibitor, with FPA008, Five Prime's monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R). The Phase 1a/1b study will evaluate the combination of Opdivo and FPA008 as a potential treatment option for patients with non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, pancreatic cancer, colorectal cancer and malignant glioma. Bristol-Myers Squibb has proposed the name Opdivo, which, if approved by health authorities, will serve as the trademark for nivolumab.
BMY: 58.75 (-0.93), FPRX: 22.13 (-1.12)
Five Prime Therapeutics (FPRX) Upgraded From Sell to Hold
at The Street - Tue Nov 18, 8:19AM CST
Five Prime Therapeutics (FPRX) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.
FPRX: 22.13 (-1.12)
Five Prime Therapeutics Initiates Dosing of Rheumatoid Arthritis Patients in Its Phase 1 Clinical Trial of FPA008
GlobeNewswire - Mon Nov 17, 3:50PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated dosing of rheumatoid arthritis (RA) patients in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R). FPA008 is being developed as a potential treatment for RA and solid tumors. FPA008 has two modes of action in RA, blocking the production of multiple inflammatory cytokines and directly inhibiting the activity of osteoclasts, thus preventing bone erosion.
FPRX: 22.13 (-1.12)
Five Prime Therapeutics to Present Data From Healthy Volunteer Cohorts in Phase 1 Trial of FPA008 at the 2014 ACR/ARHP Annual Scientific Meeting
GlobeNewswire - Thu Nov 13, 3:08PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, announced that it will present results from the healthy volunteer cohorts in its Phase 1 clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF-1R). The results will be featured in a poster presentation titled "A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF-1R) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results" at the 2014 American College of Rheumatology and the Association of Rheumatology Health Professionals (ACR/ARHP) Annual Scientific Meeting. The meeting is being held November 14-19, 2014 in Boston, Massachusetts, and the poster presentation is scheduled to take place on Monday, November 17 from 9:00 am to 11:00 am, with the poster viewable from 8:30 am to 4:00 pm. (Presentation Number 1493). The abstracts are available in the online meeting supplement: http://www.acrannualmeeting.org/wp-content/up...ement2.pdf.
FPRX: 22.13 (-1.12)
